Best GLP-1 for Weight Loss: Clinical Factors & Personalization

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The question 'What's the best GLP-1 for weight loss?' has no single answer because medication selection depends on clinical evidence, individual physiology, and medical history rather than a one-size-fits-all approach. Recent data shows GLP-1 receptor agonists produce weight loss of 15–22% of body weight over 68 weeks, but outcomes vary significantly between individuals and medication types.

Selecting the right GLP-1 requires understanding how your body may respond based on biomarkers, genetic factors, and specific clinical goals. PlexusDx focuses on precision wellness by integrating genetic insights with clinical evidence, helping you and your provider evaluate options more strategically rather than relying on marketing claims or trial-and-error.

Understanding GLP-1 Efficacy and Mechanism Differences

GLP-1 receptor agonists work by slowing gastric emptying, reducing appetite signaling, and improving glucose control. However, efficacy varies: semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) show different weight loss profiles in clinical trials. Tirzepatide, which targets both GLP-1 and GIP receptors, demonstrated up to 22.5% weight loss in SUMO trials, while semaglutide showed approximately 17.4% in STEP trials.

These differences matter, but individual response can differ significantly from trial averages. Factors like baseline metabolic health, insulin sensitivity, gut hormone signaling patterns, and genetic variations in GLP-1 and GIP receptor pathways influence real-world outcomes. Your provider should consider both published evidence and your personal metabolic profile when evaluating which medication may be most suitable.

Clinical Factors That Influence GLP-1 Selection

Choosing the right GLP-1 involves evaluating multiple clinical dimensions beyond weight loss potential. Consideration of your medical history, concurrent medications, gastrointestinal tolerance, renal function, cardiovascular status, and diabetes risk profile helps narrow options. Additionally, injection-only versus oral formulation availability and cost accessibility affect real-world feasibility.

Your provider should also assess baseline markers like HbA1c, fasting glucose, lipid profile, and inflammatory markers. These biomarkers provide baseline context for how a GLP-1 may benefit your metabolic health beyond weight reduction. Some patients prioritize rapid weight loss; others prioritize cardiovascular benefit or improved glucose control. These distinct goals may guide different medication choices.

Clinical Consideration	Why It Matters for GLP-1 Selection
Baseline BMI and weight loss goal	Higher BMI may benefit from agents with stronger efficacy data; individual targets guide dose titration strategy
HbA1c and glucose control status	Prediabetic or diabetic patients may prioritize glucose benefit alongside weight loss; impacts medication choice
Gastrointestinal tolerance history	Nausea and GI side effects are common; prior GI sensitivity may influence formulation (oral vs. injection) or agent selection
Cardiovascular and renal markers	Existing heart disease, hypertension, or eGFR status influence safety profile and provider recommendation
Genetic predispositions in peptide pathways	Variants in GLP1R, GIPR, and FTO genes may correlate with individual response patterns; supports more informed discussion

The Role of Genetic Predisposition Testing in GLP-1 Evaluation

Genetic variants in peptide hormone pathways—such as GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609—can correlate with differences in how individuals respond to GLP-1 therapy. These variants influence receptor sensitivity, baseline appetite signaling, and metabolic regulation. Understanding your genetic context may help provide background for why certain GLP-1 formulations might align better with your individual biology.

The PlexusDx Precision Peptide Genetic Test reveals predispositions in these pathways, offering context that should be interpreted by a qualified healthcare provider. This information does not predict guaranteed outcomes or exact medication response, but it can support a more informed conversation about which GLP-1 option may be worth discussing with your provider. Combined with clinical markers and medical history, genetic insights contribute to a more personalized evaluation framework.

Safety, Eligibility, and When to Consult Your Provider

GLP-1 agonists are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe kidney disease, acute pancreatitis, or diabetic retinopathy requiring treatment. Pregnancy and breastfeeding require careful consideration. Your provider must conduct a thorough medical evaluation before recommending any GLP-1 therapy and select the safest option for your individual profile.

Common side effects include nausea, vomiting, constipation, and diarrhea—typically mild to moderate and improving over time. However, rare serious adverse events such as pancreatitis or gallbladder complications require immediate medical attention. Before starting any GLP-1, discuss your full medical history, current medications, family history, and lifestyle goals with a licensed healthcare provider who can evaluate all factors and monitor your response over time.

How PlexusDx Supports a More Personalized Approach

PlexusDx's approach to GLP-1 selection integrates genetic context into clinical decision-making. The Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes—pathways directly involved in appetite regulation and GLP-1 receptor sensitivity. While genetic variants do not determine medication response, they may help provide context for why your body may have certain metabolic characteristics that could influence which GLP-1 option deserves consideration.

Your test results reveal predispositions in peptide signaling pathways—not exact medication responses or guaranteed outcomes. For example, certain GLP1R or GIPR variants may correlate with baseline appetite patterns or receptor sensitivity differences. This information should be interpreted with a qualified healthcare provider who can integrate genetic insights with your clinical markers, medical history, and personal goals to guide medication selection.

Combining PlexusDx genetic results with biomarker assessment and clinical evaluation supports more informed conversations with your healthcare provider about GLP-1 options. Rather than guessing which medication might work best, you have genetic and biomarker context that, alongside medical evidence, helps create a personalized framework for decision-making and monitoring your response.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.